businesspress24.com - Atossa Genetics to Present at Two Upcoming Investor Conferences
 

Atossa Genetics to Present at Two Upcoming Investor Conferences

ID: 1240442

(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 06/26/13 -- (NASDAQ: ATOS), the Breast Health Company™, today announced that Kyle Guse, CFO and General Counsel, will be presenting at two upcoming investor conferences: the JMP Securities Healthcare Conference in New York City and the Life Science Innovation Northwest 2013 Conference in Seattle.

The JMP Securities Healthcare Conference presentation will take place on Tuesday, July 9, 2013, at 2:00 pm Eastern Time at the St. Regis Hotel. The Life Science Innovation Northwest 2013 Conference presentation will take place on Wednesday, July 10, 2013, at 10:45 am Pacific Time at the Washington State Convention Center.



Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests, including its ForeCYTE Breast Health Test which can detect precursors to breast cancer up to eight years before mammography.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa and its medical devices, please visit . For additional information on the ForeCYTE test and the National Reference Laboratory for Breast Health, please visit .





Atossa Genetics, Inc.
Kyle Guse
Chief Financial Officer and General Counsel
800-351-3902


Matthew D. Haines (Investors)
Managing Director
MBS Value Partners
212-710-9686




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Portola Announces Oral Presentation of Phase 2 Data on PRT4445, Factor Xa Inhibitor Antidote, at 2013 International Society on Thrombosis and Haemostasis Congress
Aeolus' AEOL 10150 Significantly Improves Survival in Animals Exposed to Mustard Gas
Bereitgestellt von Benutzer: Marketwired
Datum: 26.06.2013 - 06:30 Uhr
Sprache: Deutsch
News-ID 1240442
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SEATTLE, WA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 89 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Atossa Genetics to Present at Two Upcoming Investor Conferences
"
steht unter der journalistisch-redaktionellen Verantwortung von

Atossa Genetics, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Atossa Genetics, Inc.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 75


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.